TSPO and neurodegenerative disease: While PVE can lead to false-positive findings of reduced FDG uptake in neurodegenerative diseases [34], tracers aiming to measure a target elevation in neurodegenerative diseases, such as β-amyloid [23,24], tau [35,36] or TSPO ligands, can be compromised in their sensitivity.